基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A biomarker study in Peruvian males with breast cancer.
A biomarker study in Peruvian males with breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
男性 BC 通常为 ER 和 AR 阳性,且为 Luminal-A 型。MMR 缺失和 PIK3CA 突变不常见。在我们的南美国家人群中,分期和分级可预测总生存期。
男性乳腺癌(BC)的发病率极低,且肿瘤特征与其女性对应疾病有所不同。女性乳腺癌的临床和病理特征因种族而异。TIL(肿瘤浸润淋巴细胞)水平、错配修复(MMR)蛋白缺失、雄激素受体(AR)表达以及 PIK3CA 基因突变是女性 BC 生物治疗反应的预测性生物标志物。关于非白种人种族男性 BC 患者的临床和病理特征以及预测性生物标志物的信息有限。
探讨秘鲁人群中男性BC肿瘤的临床病理特征和生物标志物及其预后价值。
本研究观察了2004年1月至2018年6月期间诊断的54例秘鲁男性浸润性BC患者的单机构系列。对具有可用石蜡材料的病例前瞻性评估了标准病理特征、TIL水平、MMR蛋白、AR免疫组化染色和PIK3CA基因突变。玻片扫描后,还通过软件计算了AR和雌激素受体(ER)阳性细胞的百分比。统计分析包括关联检验、组内相关检验和Kaplan Meier总生存曲线。
中位年龄为63岁,在我们的男性乳腺肿瘤中,大多数病例为ER阳性(85.7%)、HER2阴性(87.2%)、Luminal-A表型(60%)和临床II期(41.5%)。中位TIL为10%,较高水平倾向于与Luminal-B表型和更高分级相关。AR阳性见于85.3%,并与ER相关(组内指数为0.835,P < 0.001)。MMR蛋白缺失见于15.4%,PIK3CA突变(H1047R)见于14.3%(属于Luminal-A表型)。MMR蛋白缺失与AR阴性相关(P = 0.018),但与ER(P = 0.43)或TIL(P = 0.84)无关。早期分期(P < 0.001)和较低分级(P = 0.006)与更长的总生存期相关。ER状态、表型、AR状态、TIL水平、MMR蛋白缺失及PIK3CA突变均与生存无关(P > 0.05)。
Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) expression, and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC. There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC. AIM: To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population.
This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018. Standard pathological features, TIL levels, MMR proteins, AR immunohistochemistry staining, and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material. Percentage of AR and estrogen receptor (ER) positive cells was additionally calculated by software after slide scanning. Statistical analyses included association tests, intraclass correlation test and Kaplan Meier overall survival curves.
The median age was 63 years and most cases were ER-positive (85.7%), HER2 negative (87.2%), Luminal-A phenotype (60%) and clinical stage II (41.5%) among our male breast tumors. Median TIL was 10% and higher levels tended to be associated with Luminal-B phenotype and higher grade. AR-positive was found in 85.3% and was correlated with ER (intraclass index of 0.835, P < 0.001). Loss of MMR proteins was found in 15.4% and PIK3CA mutation (H1047R) in 14.3% (belonged to the Luminal-A phenotype). Loss of MMR proteins was associated with AR-negative ( P = 0.018) but not with ER ( P = 0.43) or TIL ( P = 0.84). Early stages ( P < 0.001) and lower grade ( P = 0.006) were associated with longer overall survival. ER status, phenotype, AR status, TIL level, MMR protein loss nor PIK3CA mutation was not associated with survival ( P > 0.05).
Male BC is usually ER and AR positive, and Luminal-A. MMR loss and PIK3CA mutations are infrequent. Stage and grade predicted overall survival in our South American country population.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。